SPARC (NSE: SPARC; BSE: 532872) is a biopharmaceutical company continuously innovating new therapies in oncology, neurodegeneration, and immunology.
SPARC’s value proposition lies in our brick-and-mortar infrastructure to effectively translate therapies from the bench, through clinical studies, to regulatory approval. This engine has resulted in approval of two NDAs. Our approved products are marketed by our commercial partners in the US, China, and India.
We are 400+ strong team spread across three global locations, with a vibrant research community of 350+ scientists working on a robust pipeline of clinical and preclinical programs. Our teams’ strengths span the R&D spectrum: small and large molecule drug discovery; CMC development; preclinical translation (including NDA-enabling toxicology); and clinical development and operations.
All of this makes SPARC unique among other small biopharma companies, especially single-asset or single-therapy focused companies.
We continue to build and strengthen our innovation engine with emphases on strong scientific execution, high value analytics, and aggressive portfolio management, to redefine patient care in areas of unmet need.